The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics

BACKGROUND: Patients with inflammatory bowel disease (IBD) may have a modified immune response to SARS-CoV-2. The objectives were to evaluate the prevalence of COVID-19 in patients treated with infliximab or vedolizumab, to analyze the factors associated with the infection, the impact of treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Lelong, Margaux, Josien, Régis, Coste-Burel, Marianne, Rimbert, Marie, Bressollette-Bodin, Céline, Nancey, Stéphane, Bouguen, Guillaume, Allez, Matthieu, Serrero, Mélanie, Caillo, Ludovic, Rouillon, Cléa, Blanc, Pierre, Laharie, David, Olivier, Raphaël, Peyrin-Biroulet, Laurent, Dib, Nina, De Maissin, Astrid, Montuclard, Céline, Trang-Poisson, Caroline, Vavasseur, Fabienne, Gallot, Géraldine, Berthome, Mathilde, Braudeau, Cécile, Chevreuil, Justine, Bourreille, Arnaud, Le Berre, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494533/
https://www.ncbi.nlm.nih.gov/pubmed/37701431
http://dx.doi.org/10.3389/fimmu.2023.1243898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494533/
https://www.ncbi.nlm.nih.gov/pubmed/37701431
http://dx.doi.org/10.3389/fimmu.2023.1243898

Ejemplares similares